Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

In a challenging market environment, DFLI, the stock for Chardan Nextech Acquisition 2, has reached a 52-week low, dipping to $2.49. According to InvestingPro analysis, the company's financial health ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

Eyenovia, Inc., an ophthalmic technology company, has announced it is consulting with Chardan as its financial advisor to explore various strategic alternatives, including potential business ...

Eyenovia (EYEN) has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from ...

Chardan initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $24 price target The firm cites the potential of the company’s lead asset zorevunersen for the treatment of Dravet ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy 5 Reasons Why Vuzix Is One Of Chardan Capital's Top Picks In 2018 Solid Biosciences Snags Bullish ...

Chardan Capital currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($2.89) per share.

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...